Author

Xiaohong Han

3 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

Simultaneous Quantification of Vedolizumab, Ustekinumab, and Infliximab in Human Serum by LC-MS/MS: Application to Therapeutic Drug Monitoring in Inflammatory Bowel Disease

Purpose: With the expanding use of therapeutic monoclonal antibodies (mAbs) in inflammatory bowel disease (IBD), there is a critical need for robust, multiplex analytical tools to support therapeutic drug monitoring (TDM) and pharmacokinetic studies. This study aimed to develop and validate a rapid and sensitive liquid...

Yan-Bao Zhang, Na Wang, Wei-Yang Zheng et al. · Drug Design, Development and... · 0 citations

Clinical trial Open access Aug 2026

Three-year adjuvant treatment of icotinib in stage II-IIIA EGFR-mutated lung adenocarcinoma (ICWIP): a randomized, double-blind, placebo-controlled phase 3 trial

This multi-center, double-blind, placebo-controlled, randomized phase 3 trial (ICWIP) assessed the efficacy and safety of 3-year icotinib adjuvant treatment versus placebo in patients with completely resected stage II-IIIA epidermal growth factor receptor (EGFR) mutated lung adenocarcinoma who had completed four cycles...

Yu-Tao Liu, Le Tang, Xiao-Hong Han et al. · Signal Transduction and Targ... · 0 citations

Aug 2026

Development and validation of an HPLC-MS/MS method for the quantification of Aficamten in human plasma and urine and application to a clinical pharmacokinetic study.

An innovative, rapid, and highly sensitive HPLC-MS/MS approach for quantifying aficamten concentrations in human plasma and urine is established and critical validation parameters including matrix effects, extraction recovery, carryover, and stability were assessed.

Xiao-Fei Wu, Aijing Liu, Adrienne Griffith et al. · Journal of chromatography. B... · 0 citations